Overview

Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus

Status:
Completed

Trial end date:
2016-04-14

Target enrollment:

Participant gender:

Summary

This trial is conducted in Europe. The aim of this trial is to compare pharmacodynamic (the effect of the investigated drug on the body) and pharmacokinetic (the exposure of the trial drug in the body) properties of insulin degludec and insulin glargine 300 U/mL at steady-state conditions in subjects with type 1 diabetes mellitus.

Phase:

Phase 1

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Insulin
Insulin Glargine
Insulin, Globin Zinc
Insulin, Long-Acting